Stockscreener 앱 받기
7.91
30.31%
-3.44
시간 외 거래:
8.10
0.19
+2.40%
전일 마감가:
$11.35
열려 있는:
$9.75
하루 거래량:
3.73M
Relative Volume:
11.73
시가총액:
$146.55M
수익:
$1.54M
순이익/손실:
$-78.54M
주가수익비율:
-1.3232
EPS:
-5.978
순현금흐름:
$-64.50M
1주 성능:
-13.55%
1개월 성능:
-21.37%
6개월 성능:
-33.42%
1년 성능:
+6.89%
1일 변동 폭
$7.73
$10.00
1주일 범위
$7.73
$12.88
52주 변동 폭
$6.72
$20.56
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Company Profile
명칭
Corbus Pharmaceuticals Holdings Inc
전화
617-963-0103
주소
500 RIVER RIDGE DRIVE, NORWOOD, MA
Compare CRBP vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CRBP
Corbus Pharmaceuticals Holdings Inc
|
7.91 | 210.29M | 1.54M | -78.54M | -64.50M | -5.978 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-30 | 재개 | B. Riley Securities | Buy |
| 2025-02-28 | 개시 | William Blair | Outperform |
| 2024-12-02 | 개시 | Piper Sandler | Overweight |
| 2024-07-30 | 개시 | Wedbush | Outperform |
| 2024-07-22 | 재개 | H.C. Wainwright | Buy |
| 2024-06-26 | 개시 | B. Riley Securities | Buy |
| 2024-06-03 | 재확인 | Oppenheimer | Outperform |
| 2024-05-13 | 개시 | RBC Capital Mkts | Outperform |
| 2024-03-06 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-09-08 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2020-09-08 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-09-08 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-09-08 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2020-07-07 | 개시 | ROTH Capital | Buy |
| 2020-06-17 | 개시 | BTIG Research | Buy |
| 2020-03-26 | 개시 | Nomura | Buy |
| 2019-04-05 | 개시 | Jefferies | Buy |
| 2019-03-20 | 개시 | Oppenheimer | Outperform |
| 2019-01-11 | 재확인 | Cantor Fitzgerald | Overweight |
| 2018-12-26 | 개시 | H.C. Wainwright | Buy |
| 2018-12-07 | 개시 | RBC Capital Mkts | Outperform |
| 2018-10-24 | 개시 | B. Riley FBR | Buy |
| 2018-01-19 | 개시 | Raymond James | Outperform |
| 2017-12-14 | 재확인 | Cantor Fitzgerald | Overweight |
| 2017-11-08 | 재확인 | Noble Financial | Buy |
| 2017-09-29 | 재개 | Noble Financial | Buy |
| 2017-03-30 | 재확인 | Cantor Fitzgerald | Overweight |
| 2016-11-15 | 재확인 | JMP Securities | Mkt Outperform |
| 2016-11-11 | 재확인 | Noble Financial | Buy |
모두보기
Corbus Pharmaceuticals Holdings Inc 주식(CRBP)의 최신 뉴스
CRBP Reiterated by HC Wainwright & Co. -- Price Target Maintained at $40 - GuruFocus
Corbus Pharmaceuticals (CRBP) Reports Promising Data on CRB-701 Trial - GuruFocus
Corbus Pharmaceuticals Stock (CRBP) Opinions on Updated CRB-701 Cancer Data Release - Quiver Quantitative
Corbus Pharmaceuticals (CRBP) Analyst Sees Mispriced Weakness - GuruFocus
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Corbus Pharma (CRBP) Faces Premarket Decline Following Phase 1/2 Trial Data - GuruFocus
Corbus Pharmaceuticals Holdings, Inc. (CRBP) Discusses Clinical Data Update From Phase 1/2 Study of CRB-701 Presented at ASCOSlideshow (NASDAQ:CRBP) 2026-05-26 - Seeking Alpha
Corbus Pharmaceuticals stock falls on trial data release By Investing.com - Investing.com Australia
Corbus Pharmaceuticals stock falls on trial data release - Investing.com
CRB-701 data advances Corbus (NASDAQ: CRBP) OPSCC and cervical plans - Stock Titan
Corbus slips on trial data for cancer candidate (CRBP:NASDAQ) - Seeking Alpha
Corbus Pharmaceuticals Holdings Inc Pre-2026 ASCO Conference Call Transcript - GuruFocus
CRBP: CRB-701 and CRB-913 delivered promising efficacy and safety in cancer and obesity studies - TradingView
Mizuho raises Corbus Pharmaceuticals stock price target to $44 on ASCO data confidence - Investing.com Canada
CRBP: CRB-701 demonstrates strong efficacy and safety in 2L OPSCC and cervical cancer, with registrational trials planned - TradingView
Corbus Pharmaceuticals reports updated CRB-701 phase 1/2 clinical data demonstrating robust activity in 2L oropharyngeal and cervical cancers - marketscreener.com
Corbus Pharmaceuticals Reports Updated CRB-701 Phase 1/2 Clinical Data Demonstrating Robust Activity in 2L Oropharyngeal and Cervical Cancers - Yahoo Finance
Corbus Pharmaceuticals teases key ASCO cancer data, late-summer obesity readout - MSN
Mizuho Securities Maintains Corbus Pharmaceuticals(CRBP.US) With Buy Rating, Raises Target Price to $44 - Moomoo
CRBP Maintained by Mizuho -- Price Target Raised to $44.00 - GuruFocus
Corbus Pharmaceuticals Holdings Inc. stock underperforms Friday when compared to competitors - MarketWatch
Corbus (CRBP) Chief Business Officer receives RSUs and 192,300 stock options - Stock Titan
Corbus (NASDAQ: CRBP) CBO Nishant Saxena reports holding 3,500 shares - Stock Titan
Corbus Pharmaceuticals Is Maintained at Outperform by Mizuho - Moomoo
Colliers facilitates 36,471 s/f lease renewal for Corbus Pharmaceuticals - NEREJ
Mizuho raises Corbus Pharmaceuticals stock price target on ASCO preview By Investing.com - Investing.com Canada
Corbus Pharmaceuticals Announces the Appointment of Nishant Saxena as Chief Business Officer and Schedules a Pre-2026 ASCO CRB-701 Data Conference Call - Sahm
Corbus Pharmaceuticals Teases Key ASCO Cancer Data, Late-Summer Obesity Readout - Barchart.com
Corbus Pharmaceuticals Announces the Appointment of Nishant Saxen - The National Law Review
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
Corbus Pharmaceuticals (CRBP) grants RSUs and stock options to director - Stock Titan
Corbus Pharmaceuticals (CRBP) director granted RSUs and 12,300 stock options - Stock Titan
Corbus Pharmaceuticals (CRBP) director receives RSUs and 12,300 stock options - Stock Titan
Corbus (NASDAQ: CRBP) director Anne Altmeyer receives RSU and stock option grants - Stock Titan
Equity grants increase Corbus (CRBP) director Ben Yong’s holdings - Stock Titan
Corbus (NASDAQ: CRBP) director receives RSU and stock option grants in equity package - Stock Titan
Corbus Pharmaceuticals (CRBP) director Brent Pfeiffenberger files initial Form 3 - Stock Titan
Corbus Pharmaceuticals Appoints Nishant Saxena as Chief Business Officer and Announces Pre-ASCO 2026 Data for CRB-701 in Oncology Trials - Minichart
Corbus Pharmaceuticals Appoints First Chief Business Officer - TipRanks
Corbus Pharmaceuticals announces the appointment of Nishant Saxena as chief business officer - marketscreener.com
Corbus appoints Brent Pfeiffenberger to board with equity awards - TradingView
Corbus Pharmaceuticals Holdings, Inc. announced that it will initiate a registration study of CRB-701 in second-line treatment for head and neck squamous cell carcinoma this summer. - Bitget
Corbus (NASDAQ: CRBP) hires Nishant Saxena as CBO, plans CRB-701 data call - Stock Titan
Corbus Pharmaceuticals Announces the Appointment of Nishant - GlobeNewswire
We're Keeping An Eye On Corbus Pharmaceuticals Holdings' (NASDAQ:CRBP) Cash Burn Rate - Sahm
Corbus Pharmaceuticals Holdings Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Corbus Pharmaceuticals Holdings Inc at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
Corbus Pharmaceuticals Holdings Inc. stock underperforms Monday when compared to competitors - MarketWatch
Understanding Momentum Shifts in (CRBP) - Stock Traders Daily
symbol__ Stock Quote Price and Forecast - CNN
Corbus Pharmaceuticals Appoints Brent Pfeiffenberger to Bd of Directors - Moomoo
Corbus Pharmaceuticals Holdings Inc (CRBP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.98%
0.12%
자본화:
|
볼륨(24시간):